Moteur de recherche d’entreprises européennes
Financement de l’UE (6 547 157 €) : Thérapie à la psilocybine pour la détresse psychologique chez les patients en soins palliatifs Hor01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Thérapie à la psilocybine pour la détresse psychologique chez les patients en soins palliatifs
Relieving serious health-related suffering for patients in palliative and end-of-life care, be it physical, psychological, social, or spiritual, is a global ethical responsibility. However, the profound psycho-emotional and existential distress entailed by such suffering, despite often being an enormous burden for both patients and their loved ones, remains a field largely overlooked by health care providers and the scientific community. Those people may develop mood or anxiety disorder for which neither non-pharmacological nor pharmacological interventions exist. In this context, we believe it is now time to target these unmet needs in the palliative care population. We want to initiate a paradigm shift at the boundaries between palliative care, psychiatry, psychology, neuroscience, and spiritual care. Our starting point is the preliminary results being reported for administration of psilocybin, the main psychoactive compound of so-called ‘psychedelic mushrooms’, in patients with depression. The objective of our project is thus to examine the clinical effect of a cutting-edge, individualised and patient-centred, open and standardised Psilocybin Therapy, addressing these unmet needs of patients in palliative care. We will show high quality evidence via a multi-centre Randomised Clinical Trial of the value of our therapeutic model in patients (and for the following four conditions: COPD, Atypical Parkinsonian Disorders, ALS, and Multiple Sclerosis), their loved ones and care providers, in a diverse sample of the European population, in addition to better understand the mechanisms of therapeutic change of our model. Finally, our project will establish a sustainable, multi-disciplinary, ecosystem of key European stakeholders jointly contributing to the medical use of psychedelic research and innovation, paving the way towards an ethical and cost-effective deployment of such a new line of care for patients in European palliative care service providers.
| A+ Science AB | 0,00 € |
| ACADEMISCH ZIEKENHUIS GRONINGEN | 1 753 914 € |
| Association Europeenne de Psychiatrie | 99 275 € |
| Centre Expert en Technologies et Services Pour le Maintien en Autonomie a Domicile des Personnes Agees | 197 500 € |
| CTC Clinical Trial Consultants AB | 328 089 € |
| European Association for Palliative Care | 141 950 € |
| European Federation OF Neurological Associations | 80 000 € |
| Fundacao D. Anna de Sommer Champalimaud e DR. Carlos Montez Champalimaud | 506 738 € |
| Kobenhavns Universitet | 804 798 € |
| LONG ALLIANTIE NEDERLAND | 35 000 € |
| Narodni Ustav Dusevniho Zdravi | 550 311 € |
| Osmond Labs AB | 683 925 € |
| Region Hovedstaden | 250 000 € |
| RIJKSUNIVERSITEIT GRONINGEN | 300 014 € |
| STICHTING OPEN: ONDERZOEK NAAR DE PSYCHEDELISCHE ERVARING NEDERLAND | 160 375 € |
| Stiftelsen 29K Foundation | 161 269 € |
| Stiftelsen Norrsken Mind | 46 250 € |
| Stockholms Universitet | 57 500 € |
| Universidad de Navarra | 240 250 € |
| Uppsala Universitet | 150 000 € |
https://cordis.europa.eu/project/id/101137378
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
